Cell Source, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
Cell Source, Inc. (CLCS) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations of 85.00 thousand shares for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations · last filed 2026-04-07
- Cell Source, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2024 was 85.00K shares, a 96.27% decline from fiscal 2023.
- Cell Source, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2023 was 2.28M shares, a 4455.00% increase from fiscal 2022.
- Cell Source, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2022 was 50.00K shares, a 83.12% decline from fiscal 2021.
- Cell Source, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures and expirations for fiscal 2021 was 296.16K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 12 month |
|---|---|
| 2024-12-31 | 85.00K shares 10-K · filed 2026-04-07 |
| 2023-12-31 | 2.28M shares 10-K · filed 2024-06-24 |
| 2022-12-31 | 50.00K shares 10-K · filed 2023-08-08 |
| 2021-12-31 | 296.16K shares 10-K · filed 2022-04-15 |